14 Melanoma Marches down, 7 to go!
19 March 2018
The weather varied, with high temps in Canberra, Bunbury, Manly and Newcastle, while Adelaide and Bunbury bore the brunt of wind and some rain. Needless to say, all six Marches were overwhelming successes.
Bendigo, with a population of less than 100,000 people, has raised a whopping $16,000 for Melanoma Institute Australia. This is incredible and the feedback has been amazing, with the committee working tirelessly to put on what was a great event.
It was a beautiful morning in Newcastle, there was a breeze and it was very scenic down near Nobby’s beach. While emotions ran high, the sense of community was undeniable, with everyone supporting one another and all Marching for the same cause. With over 300 people attending the March, Newcastle has broken the $30,000 fundraising tally mark, which is a huge achievement.
Manly had a change of location and added an additional challenge. Participants tackled stand-up-paddle boarding on a 3km loop, while the majority Marched collectively, following the Fairlight walking path. With nearly 500 people registering at Manly, the event was a huge success.
Canberra reached big numbers with over 300 participants attending the March this year. Our country’s capital always produces a great atmosphere for Marchers to show support to those who have been affected by melanoma.
Bunbury, a small town in Western Australia held Melanoma March, and, for the first time ever included a 10km optional running track. In partnership with melanomaWA, Melanoma March Bunbury contributed to raising life-saved funds for melanoma research. Thank you to the committee and to melanomaWA for their continued support.
Thank you to all participants, committee members, supporters and to all. Melanoma March is a time to remember, honour and support those who have had or have melanoma. But there is still work to be done. We still have 7 Marches in various states to go, so let’s not lose momentum. It is time to end melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.